Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.
Also called NCT06721442
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 174 participants
- Registry
-
NCT06721442
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT06721442. Randomized; no masking; primary purpose prevention. Start 2023-01-10 (actual); primary completion 2023-12-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study
- Acronym
- DAPA-ECG
- Condition
- Arrhythmias, Cardiac
- Condition
- Diabetes Mellitus
- Intervention (Drug)
- Dapagliflozin (DAPA)
- Lead sponsor
- Beneficência Portuguesa de São Paulo
- Collaborator
- Instituto Dante Pazzanese de Cardiologia
Record details
- Record id
cardio:ct-nct06721442- Content hash
9486ab2c9c7db68ef9fe582732e2e222333483bbf754e34fee8fbc842f60c359